European Archives - Page 142 of 1053 - European Medical Journal

The Effect of Exposure to Radiofrequency Fields on Cancer Risk

A review found no strong evidence linking radiofrequency electromagnetic fields from mobile phones and other sources to an increased risk of cancer, including brain tumours.

Prolonged Anticoagulation After COVID-19 Reduces Risk of Blood Clots: ERS 2024

Findings from ERS 2024 show that continuing anticoagulation after the acute phase of COVID-19 significantly reduces the risk of venous thromboembolism in recovering patients.

Increased Cancer Risk in Patients with Graves' Disease

A new South Korean study reveals that patients with Graves’ disease, an autoimmune thyroid disorder, may have an increased risk of developing cancers

Testosterone Exposure Doesn’t Affect Oocyte Cryopreservation in Gender-Diverse Individuals

Prior testosterone exposure does not negatively affect oocyte cryopreservation outcomes in transgender and gender-diverse adolescents and young adults.

New Approach Could Cut Gestational Diabetes Tests by 50%

Gestational diabetes screening in low-income countries faces challenges due to the accessibility of oral glucose tolerance tests. A study suggests early-pregnancy HbA1c testing, could reduce OGTT reliance

EMJ Cardiology 12 [Supplement 2] 2024

The emerging class of agents targeting factor XI/XIa offers the paradigm-shifting possibility of ‘haemostasis-sparing anticoagulation’…

Factor XI/XIa Inhibition: ESC Update

The emerging class of agents targeting factor XI/XIa offers the paradigm-shifting possibility of ‘haemostasis-sparing anticoagulation’…

Blood Cancer Not Linked to Cognitive Decline in Older Adults

Older adults diagnosed with hematologic malignant neoplasms experience cognitive decline at a rate similar to normal aging.

Improving Acute Myocardial Infarction Outcomes for Patients with Diabetes

Diabetes significantly raises the risk of non-ST segment myocardial infarction, with affected patients experiencing worse short- and long-term outcomes. Despite this, they often receive less invasive care.

New CML Treatment Shows Promise, But Standard Therapy Endures

The ASC4FIRST trial highlights asciminib, a new BCR::ABL1 inhibitor, as a potential alternative to current tyrosine kinase inhibitors for chronic myeloid leukaemia